NCT04373642View on ClinicalTrials.gov

"QUAD SHOT Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer"

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 23, 2020

Primary Completion Date

January 31, 2026

Study Completion Date

October 31, 2026

Conditions
Head and Neck Cancer
Interventions
DRUG

Pebrolizumab + QUADSHOT Radiotherapy

"Treatment will consist of QUAD SHOT radiotherapy combined with pembrolizumab."

Trial Locations (1)

73104

Stephenson Cancer Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER